Search results

Skip to results

Type

Status

Last updated

Showing 1 result for c1-esterase inhibitor injection

  1. Lanadelumab for preventing recurrent attacks of hereditary angioedema (TA606)

    Evidence-based recommendations on lanadelumab (Takhzyro) for preventing recurrent attacks of hereditary angioedema in people aged 12 and over.

    Technology appraisal guidance
    Published
    16 October 2019
    View recommendations

    Sections for TA606